文献速递糖尿病

局部给予DPP-IV抑制剂可预防实验性糖尿病视网膜神经退行性变

Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes.
PubMed 文献 · Diabetologia · 2017-08-04

研究评估人及db/db小鼠视网膜和玻璃体中DPP-IV的表达与含量,并对db/db小鼠局部滴眼给予沙格列汀、西格列汀或溶媒14天。结果显示DPP-IVi可预防糖尿病诱导的胶质激活、凋亡和血管渗漏(p<0.05),且不改变血糖水平;作者认为局部给予DPP-IVi对糖尿病视网膜神经退行性变和血管渗漏有效,但不能排除与GLP-1降解无关的其他机制。

要点

  • DPP-IV存在于人玻璃体,含量约为血浆的1/100。
  • 糖尿病供者视网膜色素上皮DPP-IV显著高于非糖尿病供者(p<0.05)。
  • db/db小鼠局部滴眼DPP-IVi 14天可预防胶质激活、凋亡和血管渗漏(p<0.05)。

核心结论

  • 局部给予DPP-IVi可有效预防糖尿病视网膜神经退行性变和血管渗漏。
  • 这些效应可归因于GLP-1增强,但不能排除与防止GLP-1降解无关的其他机制。

研究设计与样本

  • 人体样本:2型糖尿病参与者8例和年龄匹配的非糖尿病个体8例的玻璃体和视网膜。
  • 动物:db/db小鼠72只和db/+小鼠28只用于表达与含量评估;干预研究纳入db/db小鼠72只,局部滴眼给予沙格列汀、西格列汀或溶媒14天。

主要发现

  • DPP-IV存在于人玻璃体,含量约为血浆的1/100。
  • 视网膜DPP-IV mRNA和蛋白含量远低于肝脏或肠道,但糖尿病供者视网膜色素上皮DPP-IV显著高于非糖尿病供者(p<0.05)。
  • db/db小鼠局部DPP-IVi治疗预防胶质激活、凋亡和血管渗漏(p<0.05),并显著预防视网膜电图功能异常。
  • DPP-IVi治疗后GLP-1和EPAC-1均显著增加(p<0.05),糖尿病诱导的GLAST下调被预防,细胞外谷氨酸浓度显著降低。
  • 上述效应均在不改变血糖水平的情况下观察到。

局限性

  • 不能排除与防止GLP-1降解无关的其他机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The main aims of the present study were: (1) to assess the expression and content of dipeptidyl peptidase IV (DPP-IV) in human and db/db mouse retinas, and in human vitreous fluid; and (2) to determine whether the topical administration of the DPP-IV inhibitors (DPP-IVi) would prevent retinal neurodegeneration and vascular leakage in db/db mice by reducing endogenous glucagon-like peptide 1 (GLP-1) degradation. METHODS: To assess the expression and content of DPP-IV, human samples of vitreous fluid and retinas were obtained from participants with type 2 diabetes (n = 8) and age-matched non-diabetic individuals (n = 8), as well as from db/db (n = 72) and db/+ (n = 28) mice. The interventional study, which included 72 db/db mice, consisted of the topical administration (eye drops) of saxagliptin, sitagliptin or vehicle for 14 days. DPP-IV mRNA levels were assessed by RT-PCR, and protein content was measured by ELISA or western blotting. GLP-1 was assessed by immunofluorescence, and its downstream effector exchange protein activated by cAMP-1 (EPAC-1) was used as a measure of GLP-1 receptor activation. Retinal analyses were performed in vivo by electroretinography and ex vivo by RT-PCR (Epac-1, Iba-1 [also known as Aif1]), western blotting (EPAC-1, glial fibrillar acidic protein [GFAP], glutamate-aspartate transporter [GLAST]) and immunofluorescence measurements (GLP-1, GFAP, ionised calcium binding adaptor molecule 1 [IBA-1], TUNEL, GLAST, albumin and collagen IV). Glutamate was quantified by HPLC. In addition, vascular leakage was examined by the Evans Blue method. RESULTS: DPP-IV was present in human vitreous fluid but in a range 100-fold less than in plasma. Both mRNA levels and protein content were much lower in the retina than in the liver or bowel, but were significantly higher in retinal pigment epithelium (RPE) from diabetic donors in comparison to non-diabetic donors (p < 0.05). Topical treatment with DPP-IVi prevented glial activation, apoptosis and vascular leakage induced by diabetes in db/db mice (p < 0.05). Moreover, it also significantly prevented diabetes-induced functional abnormalities in the electroretinogram. A significant increase of both GLP-1 and EPAC-1 was found after treatment with DPP-IVi (p < 0.05). Furthermore, GLAST downregulation induced by diabetes was prevented, resulting in a significant reduction of extracellular glutamate concentrations. All these effects were observed without any changes in blood glucose levels. CONCLUSIONS/INTERPRETATION: The topical administration of DPP-IVi is effective in preventing neurodegeneration and vascular leakage in the diabetic retina. These effects can be attributed to an enhancement of GLP-1, but other mechanisms unrelated to the prevention of GLP-1 degradation cannot be ruled out.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Hernández C, Bogdanov P, Solà-Adell C, et al. Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes. Diabetologia. 2017. PMID: 28779212. doi:10.1007/s00125-017-4388-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。